康华生物(300841.SZ)：重组六价诺如病毒疫苗(毕赤酵母)启动Ⅰ期临床试验并完成首例受试者入组

Core Viewpoint - Kanghua Biotech (300841.SZ) has officially launched Phase I clinical trials for its recombinant hexavalent norovirus vaccine (Pichia pastoris) in mainland China, marking a significant step in the development of a vaccine aimed at preventing norovirus infections and the acute gastroenteritis they cause [1] Group 1: Vaccine Development - The recombinant hexavalent norovirus vaccine (Pichia pastoris) is designed to prevent norovirus infections and the resulting acute gastroenteritis [1] - Norovirus is a major pathogen responsible for acute gastroenteritis outbreaks across all age groups globally, with no approved treatment or preventive vaccine currently available [1] - The vaccine utilizes innovative genetic engineering technology based on virus-like particles (VLPs), theoretically capable of preventing over 90% of norovirus infections and related acute gastroenteritis [1]